Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2006 for Pediatrix Medical Group, Inc., a provider of pediatric medical services. The filing is significant due to a comprehensive restatement of financial statements for prior periods (dating back to 1995) and the current period. The restatement was necessitated by an Audit Committee review of historical stock option grant practices, which identified backdating, erroneous measurement dates, and accounting errors. The company also executed a two-for-one stock split in April 2006, and all share data presented reflects this split.
Key Financial Metrics (Six Months Ended June 30, 2006)
| Metric | Value (in thousands) |
|---|---|
| Net Patient Service Revenue | $391,486 |
| Net Income | $56,885 |
| Diluted EPS | $1.16 |
| Operating Margin | 23.3% |
| Cash and Cash Equivalents | $28,845 |
| Working Capital | $20,669 |
| Net Cash Provided by Operating Activities | $57,945 |
| Total Debt (Current + Long-term) | $1,105 |
Note: The company had no outstanding principal balance on its $225 million Line of Credit as of June 30, 2006, though $25 million was utilized for letters of credit.
Material Changes vs. Prior Period
- Revenue Growth: Net patient service revenue increased 15.9% to $391.5 million compared to the prior year period. This was driven by a 46.6% contribution from acquisitions and an 8.6% increase in same-unit revenue due to higher patient volumes and pricing factors.
- Profitability: Net income increased 28.4% to $56.9 million. Operating income rose 26.1% to $91.1 million.
- Expense Increases: Practice salaries and benefits increased 15.7% primarily due to acquisition-related staffing and incentive compensation. General and administrative expenses rose 2.2%, largely due to a $7.3 million increase in stock-based compensation expense resulting from the adoption of FAS 123(R).
- Restatement Impact: The filing restates prior periods to reflect additional non-cash stock-based compensation expense. For the six months ended June 30, 2005, net income was reduced by $794,000 due to these adjustments.
Guidance, Outlook, Risks, and Unusual Items
- Restatement and Investigation: The Audit Committee identified 56 backdated grants and 584 grants with erroneous measurement dates. The company voluntarily contacted the SEC, which commenced a formal investigation. The company also faces potential inquiries from the U.S. Attorney's Office. Management concluded that current executive officers did not engage in intentional misconduct, though oversight failures were noted.
- Legal Settlements: The company finalized a $25.1 million settlement with federal and state authorities regarding Medicaid and TRICARE billing practices (1996-1999). This included a five-year Corporate Integrity Agreement with the Office of Inspector General (OIG).
- Accounting Changes: Effective January 1, 2006, the company adopted FAS 123(R), requiring fair-value accounting for stock-based compensation, significantly increasing reported expenses compared to the prior year's intrinsic value method.
- Capital Resources: The company authorized a $100 million share repurchase program in August 2007 (subsequent to the period end). It expects funds from operations and its credit facility to be sufficient for the next 12 months.
- Risks: Risks include potential further restatements, litigation related to stock options, penalties for non-compliance with the Corporate Integrity Agreement, and the impact of government billing investigations.
Key Facts for Investor Verification
- Restatement Scope: Verify the full extent of the financial restatement in the upcoming 2006 Form 10-K, which will restate data for 2004, 2005, and 2006.
- Regulatory Status: Monitor the status of the SEC and U.S. Attorney's Office investigations regarding stock option practices and the potential for further enforcement actions or penalties.
- Compliance Obligations: Review the specific requirements and potential penalties associated with the five-year Corporate Integrity Agreement with the OIG.
- Stock-Based Compensation: Assess the ongoing impact of FAS 123(R) adoption on future earnings and the company's ability to attract talent with equity incentives given the historical issues.
- Liquidity Covenants: Confirm continued compliance with the $225 million Line of Credit covenants, noting the recent extensions granted for financial statement delivery.